Parma, Italy

Barbara Karolina Wołek

This inventor holds 2 USPTO granted patents. Top assignee: Chiesi Farmaceutici S.p.a.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Barbara Karolina Wołek. Retrieved from https://idiyas.com/inventor/barbara-karolina-wołek

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 8.0


Company Filing History:


Years Active: 2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Barbara Karolina Wołek: Innovator in Pharmaceutical Chemistry

Introduction

Barbara Karolina Wołek is a prominent inventor based in Parma, Italy. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit Discoidin Domain Receptors (DDR). With a total of 2 patents to her name, her work is paving the way for new therapeutic options.

Latest Patents

Her latest patents include innovative compounds of general formula (I) that serve as DDR inhibitors. These compounds have potential applications in treating various disorders associated with DDR mechanisms. The inventions detail methods for preparing these compounds, pharmaceutical compositions containing them, and their therapeutic uses.

Career Highlights

Barbara is currently employed at Chiesi Farmaceutici S.p.a., where she continues to advance her research in pharmaceutical innovations. Her work is characterized by a commitment to improving health outcomes through scientific discovery.

Collaborations

Throughout her career, Barbara has collaborated with notable colleagues, including Laura Carzaniga and Fabio Rancati. These partnerships have enhanced her research and contributed to the success of her projects.

Conclusion

Barbara Karolina Wołek is a trailblazer in the field of pharmaceutical chemistry, with her innovative patents and collaborative spirit driving advancements in medical treatments. Her contributions are vital to the ongoing development of effective therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…